Effects of dihydroartemisinin on collagen II -induced arthritis in rats model

Journal of Sichuan University (Medical Science)

Volumn 43, Issue 6, 2012, Pages 851-854

  Wang, Yan Yan ^a   Liu, Yi Xin ^a   Xie, Qi Bing ^a   Liu, Gang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Collagen induced arthritis; Dihydroartemisinin; Rheumatoid arthritis; Type ii collagen

Indexed keywords

ARTEMISININ DERIVATIVE; COLLAGEN TYPE 2; DIHYDROARTEMISININ;

ANIMAL; ARTEMISIA; ARTHRITIS; CHEMICALLY INDUCED; DISEASE MODEL; MALE; RAT; WISTAR RAT;

ANIMALS; ARTEMISIA; ARTEMISININS; ARTHRITIS; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; MALE; RATS; RATS, WISTAR;

EID: 84870526608     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bansback NJ, Regier DA, Ara R, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs, 2005;65(4): 473-496. (Pubitemid 40469553)
2. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation? Ann Rheum Dis, 2004; (10): 1186-1194. (Pubitemid 39273491)
3. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med, 1977 146(3):857-868.
4. Wang JX, Tang W, Shi LP, et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. BrJ Pharmacol,2007; 150(5) : 652-661. (Pubitemid 46355561)
5. Sims NA, Green JR, Glatt M, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collageninduced arthritis. Arthritis Rheum,2004; 50(7): 2338-2346. (Pubitemid 38924414)
6. Cuzzocrea S, McDonald MC, Mota-Filipe H, et al Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of collagen-induced arthritis. Arthritis Rheum, 2000; 43(2): 320-328. (Pubitemid 30395740)
7. Wang CR, Chen SY, Wu CL, et al. Prophylactic adenovirusmediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum,2005; 52(4):1319-1324.
8. Takeshita M, Sugita T, Takata I. Pathological evaluation of effect of anti-rheumatic drugs on type II collagen-induced arthritis in Lewis rats. Exp Anim,1997:165-169.
9. Wang JX, Tang W, Yang ZS, et al. Suppressive effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo. Eur J Pharmacol,2007; 564(1-3): 211-218. (Pubitemid 46957514)
10. Ghany MG, Strader DB, Thomas DL., et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 2009; 49( 4) : 1335-1374.
11. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepatitis, 2009; 16( 2) : 75-90.
12. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferonalpha 2a and ribavirin combination therapy in chronic hepatitis C-a randomized study of treatment duration and ribavirin dose. Ann Int Med, 2004; 140( 5) : 346-355.
13. Yan KK, Guirgis M, Dinh T, et al. Treatment responses in asians and caucasians with chronic hepatitis C infection. World J Gastroenterol, 2008; 14 ( 21) : 3416-3420.
14. Lin CK, Liu TH, Yang SH. Nonlinear position controller design with input-output linearisation technique for an interior permanent magnet synchronous motor control system. Iet Power Electronics, 2008; 1 ( 1) : 14-26.
15. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial. Clin Infect Dis, 2008; 47 ( 10) : 1260-1269.
16. Ge DL, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009; 461 ( 7262) : 399-401.
17. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 2009; 41 ( 10) : 1100-
18. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nature Genetics, 2009; 41 ( 10) : 1105-1181.
19. Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology, 2010; 52( 6) : 1888-1896.
20. Sarasin-Filipowicz M, Christen V, Duong FH, et al. Interferon regulated gene expression in the liver determines response to treatment in chronic hepatitis C. Gastroenterology, 2008; 134 ( 4) : A758-A758.
21. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology, 2010; 52( 1) : 33-37.
22. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology, 2010; 138( 7) : 2307-2314.